A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20108 in Participants With Advanced Solid Tumors
Latest Information Update: 25 Apr 2025
At a glance
- Drugs HS 20108 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 25 Apr 2025 New trial record